Vertaling van "cardiovascular events in patients with peripheral " (Nederlands → Frans) :

Berger JS, Kranz MJ, Kittelson JM et al. Aspirin for the prevention of cardiovascular events in patients with peripheral artery disease. A meta-analysis of randomized trials.
Fowkes FG, Price JF, Stewart MCW et al. Aspirin for prevention of cardiovascular events in a general population screened for a low ankle brachial index: a randomized controlled trial.

Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-bli Lancet 362 : 782-788(2003)
Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-bl Lancet 362 : 782-788(2003)

Inhaled anticholinergics and risk of major cardiovascular events in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis.
of major cardiovascular events in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis.

De auteurs tonen zich eveneens bezorgd over deze verhoogde cardiovasculaire mortaliteit (‘The higher rate of fatal cardiovascular events with olmesartan . is of concern’).
Les auteurs ont également exprimé leur inquiétude devant cette mortalité cardiovasculaire accrue (‘The higher rate of fatal cardiovascular events with olmesartan . is of concern’).

2011: Rooke TW, Hirsch AT, Misra S et al. 2011 ACCF/AHA Focused update of the guideline for the management of patients with peripheral artery disease.
Hirsch AT, Haskal ZJ, Hertzer NR et al. ACC/AHA 2005 Guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric and abdominal aortic): Executive summary.

*patients with various dideases as gastrointestinal, cardiovascular, neurologic, ocular, dermatologic, rheumatoid, renal, endocrinologic or unspecified diseases
Lee 1999, Bjelakovic Cochrane 2008 mortality, Hennekens 1996, Lin 2009, Hercberg 2004, Lonn 2005, Bjelakovic Cochrane 2008 gastrointestinal cancers, Lippman 2009, Gaziano 2009

Submission for US approval of Diovan (valsartan) for the prevention of new onset diabetes in hypertensive patients with impaired glucose tolerance and increased cardiovascular risk was achieved in July.
médicament qui prévient l’apparition du diabète et une hausse des risques cardiovasculaires chez les patients présentant une tolérance au glucose diminuée.

The FDA is reviewing Exjade safety information specifically on the risk of adverse events in patients with myelodysplastic syndrome (MDS) compared to patients without these conditions.
La FDA examine les informations concernant l’innocuité d’Exjade en particulier par rapport au risque d’effets secondaires chez les patients atteints du syndrome myélodysplasique (MDS) en comparaison des malades qui en sont indemnes.